ABIOMED, Inc. (ABMD) Position Held by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. held its stake in ABIOMED, Inc. (NASDAQ:ABMD) during the second quarter, Holdings Channel reports. The institutional investor owned 9,592 shares of the medical equipment provider’s stock at the end of the second quarter. YHB Investment Advisors Inc.’s holdings in ABIOMED were worth $1,375,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Northwestern Mutual Investment Management Company LLC raised its stake in ABIOMED by 0.4% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 6,978 shares of the medical equipment provider’s stock worth $874,000 after buying an additional 25 shares during the period. Capstone Asset Management Co. raised its stake in ABIOMED by 1.1% in the second quarter. Capstone Asset Management Co. now owns 6,410 shares of the medical equipment provider’s stock worth $919,000 after buying an additional 70 shares during the period. PNC Financial Services Group Inc. raised its stake in ABIOMED by 1.2% in the first quarter. PNC Financial Services Group Inc. now owns 7,842 shares of the medical equipment provider’s stock worth $982,000 after buying an additional 95 shares during the period. Texan Capital Management raised its stake in ABIOMED by 0.9% in the second quarter. Texan Capital Management now owns 11,779 shares of the medical equipment provider’s stock worth $1,688,000 after buying an additional 100 shares during the period. Finally, World Asset Management Inc raised its stake in ABIOMED by 4.3% in the second quarter. World Asset Management Inc now owns 2,966 shares of the medical equipment provider’s stock worth $425,000 after buying an additional 122 shares during the period. 90.68% of the stock is currently owned by institutional investors.

ABIOMED, Inc. (ABMD) opened at 146.44 on Thursday. The firm has a 50-day moving average of $143.76 and a 200-day moving average of $128.87. The company has a market capitalization of $6.43 billion, a P/E ratio of 85.64 and a beta of 0.20. ABIOMED, Inc. has a 52 week low of $95.14 and a 52 week high of $149.34.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. The business had revenue of $132.47 million for the quarter, compared to the consensus estimate of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The business’s revenue was up 28.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.29 EPS. Analysts anticipate that ABIOMED, Inc. will post $2.24 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by [[site]] and is owned by of [[site]]. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at [[permalink]].

A number of analysts recently weighed in on the stock. BidaskClub lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Piper Jaffray Companies reissued an “overweight” rating and issued a $160.00 price objective (up from $145.00) on shares of ABIOMED in a research report on Thursday, July 27th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “strong-buy” rating and set a $163.00 price objective on the stock in a research report on Thursday, July 13th. William Blair reissued an “outperform” rating on shares of ABIOMED in a research report on Thursday, June 8th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $140.00 price objective (up from $135.00) on shares of ABIOMED in a research report on Monday, July 10th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $154.00.

In other news, VP Michael G. Howley sold 18,279 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $133.56, for a total value of $2,441,343.24. Following the sale, the vice president now directly owns 62,105 shares of the company’s stock, valued at approximately $8,294,743.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Michael G. Howley sold 600 shares of the business’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $132.84, for a total transaction of $79,704.00. Following the completion of the sale, the vice president now directly owns 48,305 shares in the company, valued at $6,416,836.20. The disclosure for this sale can be found here. Insiders sold a total of 70,129 shares of company stock worth $9,508,475 over the last three months. Insiders own 7.00% of the company’s stock.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).